Report of the SANDOZ satellite session at the conference CARDIOLIPID 2016 Meeting Proceedings
Article Sidebar
Published:
Dec 31, 2016
Keywords:
dyslipidaemia, guidelines, satellite session
Main Article Content
Abstract
Conference CARDIOLIPID 2016 which took place in Gdynia on 9–11 September 2016 was devoted to issues related to lipid disorders, and especially to the latest guidelines for the management of dyslipidaemias which were announced a week earlier during the congress of the European Society of Cardiology in Rome. On the second day of the conference there was a satellite session during which two experts responded to eight authentic questions raised by the doctors. This article presents a brief summary of this session.
Article Details
How to Cite
Barylski , M. (2016). Report of the SANDOZ satellite session at the conference CARDIOLIPID 2016. Medycyna Faktow (J EBM), 9(4(33), 378-380. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2216
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Cannon C.P.: Balancing the benefits of statins versus a new risk-diabetes. Lancet 2010; 375(9716): 700-701.
2. Catapano A.L., Graham I., De Backer G. et al.; Task Force Members; Additional Contributor: 2016 ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 2016 [w druku].
3. Law M.R., Wald N.J., Rudnicka A.R.: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423.
4. Wożakowska-Kapłon B., Filipiak K.J., Mamcarz A. et al.: Aktualne problemy dyslipidemii w Polsce – II Deklaracja Sopocka. Stanowisko grupy ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Kardiol. Pol. 2014; 72: 847-853.
5. Stroes E.S., Thompson P.D., Corsini A. et al.; European Atherosclerosis Society Consensus Panel: Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J. 2015; 36(17): 1012-1022.
2. Catapano A.L., Graham I., De Backer G. et al.; Task Force Members; Additional Contributor: 2016 ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 2016 [w druku].
3. Law M.R., Wald N.J., Rudnicka A.R.: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423.
4. Wożakowska-Kapłon B., Filipiak K.J., Mamcarz A. et al.: Aktualne problemy dyslipidemii w Polsce – II Deklaracja Sopocka. Stanowisko grupy ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Kardiol. Pol. 2014; 72: 847-853.
5. Stroes E.S., Thompson P.D., Corsini A. et al.; European Atherosclerosis Society Consensus Panel: Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J. 2015; 36(17): 1012-1022.